Linked Data API

Show Search Form

Search Results

1141383
registered interest false more like this
date less than 2019-07-23more like thismore than 2019-07-23
answering body
Home Office more like this
answering dept id 1 more like this
answering dept short name Home Office more like this
answering dept sort name Home Office more like this
hansard heading Visas: Migrant Workers more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for the Home Department, what the requirements are for an organisation to qualify to sponsor Tier 2 and Tier 5 visas; and how many organisations meet those qualifications. more like this
tabling member constituency Feltham and Heston more like this
tabling member printed
Seema Malhotra more like this
uin 281086 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-31more like thismore than 2019-07-31
answer text <p>The requirements to become a sponsor and maintain this status are set out in the Tiers 2 and 5: guidance for sponsors. Currently, there are more than 30,000 organisations that are licenced sponsors.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy remove filter
question first answered
remove maximum value filtermore like thismore than 2019-07-31T15:05:38.407Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4253
label Biography information for Seema Malhotra remove filter
1136653
registered interest false more like this
date less than 2019-07-03more like thismore than 2019-07-03
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Diabetes more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the prevalence of (a) Type 1 and (b) Type 2 diabetes in each local authority area in each of the last three years; what steps his Department is taking to tackle the prevalence of diabetes; and what assessment he has made of the effectiveness of his Department's policy on tackling diabetes. more like this
tabling member constituency Feltham and Heston more like this
tabling member printed
Seema Malhotra more like this
uin 272840 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-12more like thismore than 2019-07-12
answer text <p>Data on the prevalence of type 1 and type 2 diabetes is not available at local authority level.</p><p>The prevalence of both type one and type two diabetes, combined, is monitored and published via the Quality and Outcomes Framework (QOF) and the National Diabetes Audit (NDA) provides information on the number with each condition separately at clinical commissioning group and general practice level. The QOF can be viewed at the following link:</p><p><a href="https://qof.digital.nhs.uk/" target="_blank">https://qof.digital.nhs.uk/</a></p><p>The NDA can be viewed at the following link:</p><p><a href="https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit" target="_blank">https://digital.nhs.uk/data-and-information/publications/statistical/national-diabetes-audit</a></p><p>Steps to reduce the increase in the prevalence of type 2 diabetes are being led via the Healthier You NHS Diabetes Prevention Programme. This programme can be viewed at the following link:</p><p><a href="https://www.england.nhs.uk/diabetes/diabetes-prevention/" target="_blank">https://www.england.nhs.uk/diabetes/diabetes-prevention/</a></p><p>Significant funding and commitments to improving services for those with type 1 and type 2 diabetes have also been made in the NHS Long Term Plan. The NHS Long Term Plan can be viewed at the following link:</p><p><a href="https://www.longtermplan.nhs.uk/" target="_blank">https://www.longtermplan.nhs.uk/</a></p><p>A first progress report covering early implementation of the Healthier You Diabetes Prevention Programme, including numbers of referrals and uptake in its first year, was published as a short report in Diabetic Medicine and can be accessed at the following link:</p><p><a href="https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13562" target="_blank">https://onlinelibrary.wiley.com/doi/full/10.1111/dme.13562</a></p><p><strong> </strong></p><p><strong> </strong></p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy remove filter
question first answered
less than 2019-07-12T11:23:20.733Zmore like thismore than 2019-07-12T11:23:20.733Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4253
label Biography information for Seema Malhotra remove filter
1136238
registered interest false more like this
date less than 2019-07-02more like thismore than 2019-07-02
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cancer: Greater London more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what comparative assessment his Department has made between the annual cancer mortality rate in (a) the London borough of Hounslow and (b) London in each of the last five years; and what steps his Department is taking to tackle cancer mortality in (i) the London borough of Hounslow and (ii) London. more like this
tabling member constituency Feltham and Heston more like this
tabling member printed
Seema Malhotra more like this
uin 272196 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-10more like thismore than 2019-07-10
answer text <p>The information is not available in the format requested.</p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy remove filter
question first answered
less than 2019-07-10T11:08:14.05Zmore like thismore than 2019-07-10T11:08:14.05Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4253
label Biography information for Seema Malhotra remove filter
1136290
registered interest false more like this
date less than 2019-07-02more like thismore than 2019-07-02
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Maraviroc more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the (a) adequacy of NHS procurement options for and (b) the affordability of Maraviroc. more like this
tabling member constituency Feltham and Heston more like this
tabling member printed
Seema Malhotra more like this
uin 272207 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-10more like thismore than 2019-07-10
answer text <p>NHS England runs a competitive framework tender process to assess availability and cost of drugs used to treat HIV. Maraviroc is currently commissioned and procured for HIV nationally through a tender framework by NHS England and NHS Improvement. The affordability of Maraviroc is similar to comparable HIV treatments.</p><p> </p><p><strong> </strong></p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy remove filter
question first answered
less than 2019-07-10T16:22:18.257Zmore like thismore than 2019-07-10T16:22:18.257Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4253
label Biography information for Seema Malhotra remove filter
1136291
registered interest false more like this
date less than 2019-07-02more like thismore than 2019-07-02
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Maraviroc: Progressive Multifocal Leukoencephalopathy more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment NHS England has made of the availability of Maraviroc to patients with progressive multifocal leukoencephalopathy. more like this
tabling member constituency Feltham and Heston more like this
tabling member printed
Seema Malhotra more like this
uin 272208 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-10more like thismore than 2019-07-10
answer text <p>We are informed by NHS England and NHS Improvement that it does not commission Maraviroc for progressive multifocal leukoencephalopathy as there is currently insufficient evidence to support its use in this condition.</p><p>NHS England and NHS Improvement have published do not commission policy for ‘Natalizumab-induced progressive multifocal leukoencephalopathy in relation to immune reconstitution inflammatory syndrome in multiple sclerosis.’</p><p>Due to a lack of evidence and as it is considered experimental, it is not currently commissioned for this indication.</p><p>Further information is available at the following link:</p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2018/03/maraviroc-for-ms-urgent-policy-statement.pdf" target="_blank">https://www.england.nhs.uk/wp-content/uploads/2018/03/maraviroc-for-ms-urgent-policy-statement.pdf</a></p><p> </p> more like this
answering member constituency South Ribble more like this
answering member printed Seema Kennedy remove filter
question first answered
less than 2019-07-10T16:06:26.687Zmore like thismore than 2019-07-10T16:06:26.687Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4253
label Biography information for Seema Malhotra remove filter
1135903
registered interest false more like this
date less than 2019-07-01more like thismore than 2019-07-01
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Liothyronine more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the value for money of prescribing Liothyronine (T3) on the NHS. more like this
tabling member constituency Feltham and Heston more like this
tabling member printed
Seema Malhotra more like this
uin 271506 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-09more like thismore than 2019-07-09
answer text <p>The Department has made no assessment. Clinical commissioning groups (CCGs) are responsible for the planning, commissioning and access to health care services for their local area.</p><p> </p><p>NHS England and NHS Improvement are working closely with CCGs on the prescribing of liothyronine to support them with the implementation of guidance for CCGs on items which should not be routinely prescribed in primary care.</p><p>This guidance includes recommendations on the use of liothyronine in line with the British Thyroid Association, who advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction. In these circumstances, where levothyroxine has failed and in line with this guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least three months duration of the drug.</p><p>Further guidance on the prescribing of liothyronine has been published by the Regional Medicines Optimisation Committee. The aim of the guidance is to make best practice on the prescribing of liothyronine clearer. CCGs are expected to have regard to national guidance, and are responsible for developing their own local approaches to its implementation taking into account local priorities and needs.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy remove filter
grouped question UIN
271507 more like this
271508 more like this
question first answered
less than 2019-07-09T13:11:47.133Zmore like thismore than 2019-07-09T13:11:47.133Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4253
label Biography information for Seema Malhotra remove filter
1135904
registered interest false more like this
date less than 2019-07-01more like thismore than 2019-07-01
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Liothyronine more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure access to Liothyronine on the NHS as an alternative to Levothyroxine. more like this
tabling member constituency Feltham and Heston more like this
tabling member printed
Seema Malhotra more like this
uin 271507 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-09more like thismore than 2019-07-09
answer text <p>The Department has made no assessment. Clinical commissioning groups (CCGs) are responsible for the planning, commissioning and access to health care services for their local area.</p><p> </p><p>NHS England and NHS Improvement are working closely with CCGs on the prescribing of liothyronine to support them with the implementation of guidance for CCGs on items which should not be routinely prescribed in primary care.</p><p>This guidance includes recommendations on the use of liothyronine in line with the British Thyroid Association, who advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction. In these circumstances, where levothyroxine has failed and in line with this guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least three months duration of the drug.</p><p>Further guidance on the prescribing of liothyronine has been published by the Regional Medicines Optimisation Committee. The aim of the guidance is to make best practice on the prescribing of liothyronine clearer. CCGs are expected to have regard to national guidance, and are responsible for developing their own local approaches to its implementation taking into account local priorities and needs.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy remove filter
grouped question UIN
271506 more like this
271508 more like this
question first answered
less than 2019-07-09T13:11:47.18Zmore like thismore than 2019-07-09T13:11:47.18Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4253
label Biography information for Seema Malhotra remove filter
1135906
registered interest false more like this
date less than 2019-07-01more like thismore than 2019-07-01
answering body
Department of Health and Social Care more like this
answering dept id 17 more like this
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Liothyronine more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent steps he has taken to ensure access to Liothyronine on the NHS for people with hypothyroidism. more like this
tabling member constituency Feltham and Heston more like this
tabling member printed
Seema Malhotra more like this
uin 271508 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2019-07-09more like thismore than 2019-07-09
answer text <p>The Department has made no assessment. Clinical commissioning groups (CCGs) are responsible for the planning, commissioning and access to health care services for their local area.</p><p> </p><p>NHS England and NHS Improvement are working closely with CCGs on the prescribing of liothyronine to support them with the implementation of guidance for CCGs on items which should not be routinely prescribed in primary care.</p><p>This guidance includes recommendations on the use of liothyronine in line with the British Thyroid Association, who advise that a small proportion of patients treated with levothyroxine continue to suffer with symptoms despite adequate biochemical correction. In these circumstances, where levothyroxine has failed and in line with this guidance, endocrinologists providing NHS services may recommend liothyronine for individual patients after a carefully audited trial of at least three months duration of the drug.</p><p>Further guidance on the prescribing of liothyronine has been published by the Regional Medicines Optimisation Committee. The aim of the guidance is to make best practice on the prescribing of liothyronine clearer. CCGs are expected to have regard to national guidance, and are responsible for developing their own local approaches to its implementation taking into account local priorities and needs.</p>
answering member constituency South Ribble more like this
answering member printed Seema Kennedy remove filter
grouped question UIN
271506 more like this
271507 more like this
question first answered
less than 2019-07-09T13:11:47.227Zmore like thismore than 2019-07-09T13:11:47.227Z
answering member
4455
label Biography information for Seema Kennedy more like this
tabling member
4253
label Biography information for Seema Malhotra remove filter